Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05765266 · ClinicalTrials.gov registry record · NA
ACP Max™ PRP System for Knee Osteoarthritis: A Feasibility Trial
A NA study, sponsored by Arthrex.
- Completed
- Registry status
- NA
- Development phase
- 45
- Enrollment target
NCT05765266: Completed NA study, sponsored by Arthrex.
NCT05765266 is a NA study that has completed, run by Arthrex. The registered enrollment target is 45 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05765266, a NA study, has completed, sponsored by Arthrex.
- COMPLETED
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
Study Summary
This study is a prospective, multicenter (up to 4 sites), randomized, double-blind, two-arm study. Forty-five (45) patients will be randomized to receive a single 4-6 ml intra-articular (IA) injection of either the output of ACP Max™ (n=30) or 6 ml of Depo-Medrol® (methylprednisolone acetate) (n=15).
Primary Outcome
A comparison of the frequency and severity of all adverse events between the investigational group and the control group at 6 months.
Interventions
- DEVICE ACP Max™
- DEVICE Depo-Medrol®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2024-05-13 |
| Est. Completion | 2026-02-09 |
| Phase | NA |
What the finished NCT05765266 record still lists
NCT05765266 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which ACP Max™ is the first listed.
NCT05765266 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05765266 about?
NCT05765266 is a clinical study titled "ACP Max™ PRP System for Knee Osteoarthritis: A Feasibility Trial". This study is a prospective, multicenter (up to 4 sites), randomized, double-blind, two-arm study. Forty-five (45) patients will be randomized to receive a single 4-6 ml intra-articular (IA) injection of either the output of ACP Max™ (n=30) or 6 ml of Depo-Medrol® (methylprednisolone acetate) (n=15)...
What is the current status of trial NCT05765266?
This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2024-05-13. Estimated completion is 2026-02-09.
What interventions are being tested in trial NCT05765266?
The interventions under investigation include: ACP Max™ (DEVICE), Depo-Medrol® (DEVICE).
Who is sponsoring clinical trial NCT05765266?
This trial is sponsored by Arthrex, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05765266's enrollment target sits among peer trials
45 1411th of 2000 higher than 578 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI